Hispanic patients show a lower risk and longer time to a second cutaneous squamous cell carcinoma than matched non-Hispanic ...
Read on to learn more about CSCC, how it can progress to become advanced, and discover ways to be proactive about your skin health. While melanoma often receives more attention, non-melanoma skin ...
Libtayo showed similar SPT rates to placebo but improved DFS in high-risk CSCC patients post-surgery and radiotherapy. The C-POST trial demonstrated Libtayo's superior DFS rates, with 81.1% at 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results